Spinocerebellar ataxia (SCA) is a group of genetic disorders characterized by progressive damage to the cerebellum, the part of the brain responsible for balance and coordination. It is caused by a mutation on one of several genes associated with SCA, including SCA1, SCA2, SCA3, SCA6, and SCA7. Symptoms of SCA include unsteady and jerky movements, difficulty with speech and swallowing, and loss of coordination. The cause of SCA is linked to genetic mutations, which can be inherited or occur spontaneously. In familial cases, a family member likely inherited the mutation from a parent or developed it on his or her own. However, some forms of SCA can arise spontaneously. In these cases, SCA is not inherited from either parent and is not passed down to the next generation. The primary symptom of SCA is progressive loss of coordination, known as cerebellar ataxia. People with SCA may have difficulty walking or performing fine motor tasks like buttoning a shirt or writing. Balance, coordination, and speech can be affected, and people with SCA may experience tremors or spasms, trouble coordinating eye movements, and difficulty with swallowing. SCA has no cure, but therapy can help treat the condition and improve quality of life. Physical therapy can help maintain muscle strength and control, while occupational therapy can help with self-care activities and daily living skills. Medication can help control the symptoms, such as reducing tremors or spasms. Speech therapy can help with communication and swallowing, and assistive devices such as wheelchairs or walkers can help improve mobility. In addition, research is being conducted to better understand the genetics of SCA and how the condition works. This research is looking for potential treatments to slow the progression of SCA and improve quality of life for those affected.
Title : Scalp acupuncture with functional electrical stimulation for the treatment children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy, Australia
Title : A structure-based strategy to target pathogenic α-synuclein in Parkinson’s disease
Salvador Ventura, Autonomous University of Barcelona, Spain
Title : Rabies: Challenges in taming the beast
Alan C Jackson, University of Calgary, Canada
Title : Designing and managing intelligent and ethical transformed health and social care ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Understanding Alzheimer's disease biomarkers across diverse populations - Opportunities and Insights for novel prevision medicine approaches
Sid O Bryant, Texas College of Osteopathic Medicine and University of North Texas Health Science Center Fort Worth, United States